Literature DB >> 24946140

Polypharmacology: challenges and opportunities in drug discovery.

Andrew Anighoro1, Jürgen Bajorath, Giulio Rastelli.   

Abstract

At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biological target, shares the spotlight with an emerging and alternative polypharmacology approach. Polypharmacology suggests that more effective drugs can be developed by specifically modulating multiple targets. It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches. In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs. In this review, we will compare advantages and disadvantages of multitarget versus combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.

Entities:  

Mesh:

Year:  2014        PMID: 24946140     DOI: 10.1021/jm5006463

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  206 in total

1.  Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry.

Authors:  Holger Franken; Toby Mathieson; Dorothee Childs; Gavain M A Sweetman; Thilo Werner; Ina Tögel; Carola Doce; Stephan Gade; Marcus Bantscheff; Gerard Drewes; Friedrich B M Reinhard; Wolfgang Huber; Mikhail M Savitski
Journal:  Nat Protoc       Date:  2015-09-17       Impact factor: 13.491

2.  A Near-IR Fluorescent Dasatinib Derivative That Localizes in Cancer Cells.

Authors:  Syed Muhammad Usama; Bosheng Zhao; Kevin Burgess
Journal:  Bioconjug Chem       Date:  2019-04-01       Impact factor: 4.774

3.  Validation strategies for target prediction methods.

Authors:  Neann Mathai; Ya Chen; Johannes Kirchmair
Journal:  Brief Bioinform       Date:  2020-05-21       Impact factor: 11.622

Review 4.  The human endogenous metabolome as a pharmacology baseline for drug discovery.

Authors:  Andreu Bofill; Xavier Jalencas; Tudor I Oprea; Jordi Mestres
Journal:  Drug Discov Today       Date:  2019-06-19       Impact factor: 7.851

5.  Computational studies to predict or explain G protein coupled receptor polypharmacology.

Authors:  Kenneth A Jacobson; Stefano Costanzi; Silvia Paoletta
Journal:  Trends Pharmacol Sci       Date:  2014-11-14       Impact factor: 14.819

6.  Binding site characterization - similarity, promiscuity, and druggability.

Authors:  Christiane Ehrt; Tobias Brinkjost; Oliver Koch
Journal:  Medchemcomm       Date:  2019-06-06       Impact factor: 3.597

7.  Diflunisal targets the HMGB1/CXCL12 heterocomplex and blocks immune cell recruitment.

Authors:  Federica De Leo; Giacomo Quilici; Mario Tirone; Francesco De Marchis; Valeria Mannella; Chiara Zucchelli; Alessandro Preti; Alessandro Gori; Maura Casalgrandi; Rosanna Mezzapelle; Marco E Bianchi; Giovanna Musco
Journal:  EMBO Rep       Date:  2019-08-14       Impact factor: 8.807

8.  Harnessing Polypharmacology with Medicinal Chemistry.

Authors:  Maria Laura Bolognesi
Journal:  ACS Med Chem Lett       Date:  2019-02-15       Impact factor: 4.345

9.  Systematic computational identification of promiscuity cliff pathways formed by inhibitors of the human kinome.

Authors:  Filip Miljković; Martin Vogt; Jürgen Bajorath
Journal:  J Comput Aided Mol Des       Date:  2019-03-26       Impact factor: 3.686

10.  Nanotopography-responsive myotube alignment and orientation as a sensitive phenotypic biomarker for Duchenne Muscular Dystrophy.

Authors:  Bin Xu; Alessandro Magli; Yoska Anugrah; Steven J Koester; Rita C R Perlingeiro; Wei Shen
Journal:  Biomaterials       Date:  2018-08-21       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.